Company intelligence / Profile preview
Akelos Inc.
New York, New York, United Statesakelosinc.com ↗
- Ownership
- Private
- Development stage
- Preclinical
01
Overview
Akelos’ lead program is a first-in-class, non-opioid drug candidate for neuropathic and chronic pain. The company’s preclinical studies have shown promising results in calming hyperactive peripheral neurons by inhibiting HCN1 channels. The lead compound has achieved preclinical safety milestones and the company has received NIH funding to advance development toward clinical trials[4][5].
- Therapeutic areas
- Neurology
- Modalities
- Small molecules (non-opioid designer molecules targeting HCN1 ion channels)[1][2][3]
- Industry
- Biotech
02
Drug pipeline
2 assets1 more asset in the full pipeline.
03
Partnerships
Weill Cornell Medicine (research collaboration)[3][5]
Beyond the preview
Go deeper on Akelos Inc..
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Akelos Inc..